Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba® (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials
Diabetes News
Tag: Tresiba
Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30
Novo Nordisk announce that the US Food and Drug Administration (FDA) has approved Tresiba® and Ryzodeg® 70/30 for the treatment of diabetes mellitus in adults after review of the class II resubmissions of the New Drug Applications (NDAs)
Novo Nordisk to cease distribution of Tresiba® in Germany
Novo Nordisk announce that the company has decided to cease distribution of its once-daily basal insulin Tresiba® (insulin degludec) in Germany following a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds
Glycosmedia is also available as an App: